國家衛生研究院 NHRI:Item 3990099045/2082

NHRI > National Institute of Infectious Diseases and Vaccinology > Ih-Jen Su(2002-2015) > Periodical Articles > Item 3990099045/2082

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/2082

Title:	Pathogenesis and mechanism of disease progression from hemophagocytic lymphohistiocytosis to Epstein-Barr virus-associated T-cell lymphoma: Nuclear factor-kappa B pathway as a potential therapeutic target
Authors:	Chuang, HC;Lay, JD;Hsieh, WC;Su, IJ
Contributors:	Division of Clinical Research;National Institute of Cancer Research
Abstract:	Epstein-Barr virus (EBV) can infect T lymphocytes and manifests as hemophagocytic lymphohistiocytosis (HLH), a distinct entity of hemophagocytic syndrome (HPS) characterized by fever, hepatosplenomegaly, cytopenia, hypercytokinemia, and systemic macrophage activation with hemophagocytosis. In a substantial percentage of HLH patients, the disease may relapse or progress to T-cell lymphoma in months to years. In the present review, the authors summarize the previous studies on the pathogenesis of HLH and the potential mechanism for the progression of disease from HLH to T-cell lymphoma. The infection of T cells by EBV could activate T cells to secrete proinflammatory cytokines, particularly tumor necrosis factor-alpha (TNF-alpha), which subsequently activate macrophages. EBV latent membrane protein-1 (LMP-1) is the viral product responsible for the activation of the TNF receptor (TNFR) associated factors/nuclear factor-kappa B (NF-kappa B)/ERK pathway to enhance cytokine secretion mediated through the suppression of the SAP/SH2D1A gene. The activation of NF-kappa B will confer resistance to TNF-alpha-induced apoptosis on EBV-infected T cells through the down-regulation of TNFR-1. Consistent with in vitro observations, EBV-associated T or natural killer/T-cell lymphoma showed constitutive activation of NF-kappa B, explaining its drug resistance, hypercytokinemia, and poor prognosis. Therefore, similar to other inflammation-associated cancers, HLH provides a unique model to study the mechanism of disease progression from a benign virus-infected disorder (HLH) to T-cell lymphoma. Inhibition of the NF-kappa B signal pathway should provide a potential target for the treatment of HLH and EBV-associated T-cell lymphoma.
Keywords:	Oncology
Date:	2007-09
Relation:	Cancer Science. 2007 Sep;98(9):1281-1287.
Link to:	http://dx.doi.org/10.1111/j.1349-7006.2007.00549.x
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1347-9032&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000248968500001
Cited Times(Scopus):	http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=34547842304
Appears in Collections:	[Ih-Jen Su(2002-2015)] Periodical Articles [Others] Periodical Articles [Huai-Chia Chuang] Periodical Articles

Files in This Item:

File	Description	Size	Format
000248968500001.pdf		780Kb	Adobe PDF	600	View/Open

Loading...